AstraZeneca and Amgen Collaborate to Develop and Commercialise Amgen’s Clinical Inflammation Portfolio
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 4 (Table of Contents)
Published: 9 Apr-2012
DOI: 10.3833/pdr.v2012.i4.1710 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca and Amgen have formed a major collaboration for the development and commercialisation of five monoclonal antibodies from Amgen’s clinical inflammation portfolio...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS